A new study, posted to the bioRxiv preprint server, has developed a single-cell atlas that presents the shared and distinct immune responses and metabolism following SARS-CoV-2 and HIV-1 infections.
More than thirty years after discovering Leber’s hereditary optic neuropathy (LHON) as the first maternally inherited disease associated with homoplasmic mtDNA mutations, we still struggle to achieve effective therapies. LHON is characterized by selective degeneration of retinal ganglion cells (RGCs) and is the most frequent mitochondrial disease, which leads to blindness young people, in particular males. Despite the causative mutations are present in all tissues, yet only a specific cell type is affected. Our deep understanding of the pathogenic mechanisms in LHON is hampered by the lack of appropriate models since investigations have been traditionally performed in non-neuronal cells. Effective in vitro models of LHON are now emerging, casting promise to speed our understanding of pathophysiology and test therapeutic strategies to accelerate translation into clinic. We here review the potentials of these new models and their impact on the future of LHON patients.
Q: How many cells/events can the immune-profiling method collect?
NA: The range for our products is typically anywhere from targeting 500 to 10,000 cells per reaction. If you wanted to go larger than that, you can use multiple reactions and aggregate the data afterwards. We do have data sets online that have a million cells in them, where multiple reactions were used and the data combined.
Q: In the immune-profiling workflow, can the cells be recovered, or is the workflow destructive?
NA: Since the cells must go through the microfluidic chip to generate the single-cell GEMs for analysis, they do become lysed in that process. You can do the reverse transcription and generate the single-cell gene-expression profiles. Since the cells are lysed in the GEMs, you are getting the gene-expression profile of the entire cell.
WCCT Global Expands Clinical and Lab Services Capacity to Meet Increasing Demand for Phase 1 and COVID-19 Vaccine Clinical Trials
Share Article
WCCT Global, Inc., a Contract Research Organization, or CRO, specializing in early phase clinical trials, is expanding its Orange County based clinical pharmacology unit and laboratory capacity to meet increasing demand during the COVID-19 pandemic, including recent demand to conduct COVID-19 vaccine clinical trials in healthy volunteers with undisclosed partners. The facility expansions should be completed by the end of January 2021.
WCCT Global clinical pharmacology unit
The comfort and safety of our study participants has always been a priority for us at WCCT